Mergers & Acquisitions ·
At a special meeting held on July 8, 2026, Esperion Therapeutics stockholders approved the Merger Agreement dated May…
ESPREsperion Therapeutics, Inc.
At a special meeting held on July 8, 2026, Esperion Therapeutics stockholders approved the Merger Agreement dated May 1, 2026, between the Company, Essence Parent Inc., and Essence MergerCo Inc. The approval allows MergerCo to merge with the Company, resulting in the Company becoming a wholly owned subsidiary of Essence Parent Inc. A quorum was established by 158,573,615 shares, representing 61.53% of the 257,693,347 issued and outstanding shares. Additionally, stockholders approved an advisory, non-binding proposal regarding executive compensation related to the merger. Esperion Therapeutics is a biopharmaceutical company focused on developing medicines for cardiovascular disease.